行情

INVA

INVA

Innoviva
NASDAQ

实时行情|Nasdaq Last Sale

13.76
+0.08
+0.58%
盘后: 13.76 0 0.00% 16:07 12/13 EST
开盘
13.70
昨收
13.68
最高
13.85
最低
13.64
成交量
58.44万
成交额
--
52周最高
20.54
52周最低
10.03
市值
13.94亿
市盈率(TTM)
4.157
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INVA 新闻

  • 隔夜要闻:美股创新高 美联储副主席称经济前景稳固
  • 新浪美股.22分钟前
  • 中概股周五整体小幅上涨 流利说大涨逾18%
  • 新浪美股.25分钟前
  • 脸书2.9万雇员银行信息被盗 财务人员汽车遭破窗抢劫
  • 新浪财经综合.36分钟前
  • 小摩CEO:对种族主义感到“厌恶” 公司仍需改进
  • 新浪美股.48分钟前

更多

所属板块

制药
+0.14%
制药与医学研究
-0.07%

热门股票

名称
价格
涨跌幅

INVA 简况

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
展开

Webull提供Innoviva Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。